PDS Biotechnology Corp
PDSBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PDSB. That does not mean none is planned.
Get an email about PDSB's next catalysts
Track PDS Biotechnology (PDSB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
PDSB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.09 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab Monotherapy | Phase 3 | Recurrent Head and Neck Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in PDS Biotechnology Corp's drug pipeline?→
CatalystAlert tracks 1 drug candidate in PDS Biotechnology Corp's (PDSB) pipeline across Phase 3. Its lead program is Pembrolizumab Monotherapy (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PDS Biotechnology Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PDS Biotechnology Corp (PDSB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PDSB biotech catalysts?→
Add PDSB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PDS Biotechnology Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.